Prognostic factors in lactic acidosis syndrome caused by nucleoside reverse transcriptase inhibitors: Report of eight cases and review of the literature

AIDS Patient Care and STDs

Volumn 18, Issue 7, 2004, Pages 379-384

  Tripuraneni, Naga S ^a   Smith, Peter R ^a   Weedon, Jeremy ^a   Rosa, Ute ^a   Sepkowitz, Douglas ^a  

^a LONG ISLAND COLLEGE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LACTIC ACID; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LYMPHOCYTE COUNT; MALE; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; VIRUS LOAD;

EID: 3343001895     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/1087291041518229     Document Type: Review

References (18)

1. Shikuma CM, Shiramuzi B. Mitochondrial toxicity associated with nucleoside reverse transcriptase inhibitor therapy. Curr Infect Dis Rep 2001;3:553-560.
2. White AJ. Mitochondrial toxicity and HIV therapy. Sex Transm Infect 2001;77:158-173.
3. Chatta G, Arieff AI, Cummings C, Tierney LM. Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann Intern Med 1993;118:37-39.
4. Freiman JP, Helfert KE, Hamrell MR, Stein DS. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS 1993;7:379-385.
5. Sundar K, Suarez M, Banogon PE, Shapiro JM. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: Report of two patients and review of the literature. Crit Care Med 1997;25:1425-1430.
6. Shaer AJ, Rasteger A. Lactic acidosis in the setting of antiretroviral therapy for the acquired immunodeficiency syndrome. Am J Nephrol 2000;20:332-338.
7. Mokrzycki MH, Harris C, May H, Laut J, Palmisano J. Lactic acidosis associated with stavudine administration: A report of five cases. Clin Infect Dis 2000;30:198-200.
8. Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs LA. Lactic acidosis and hepatic steatosis associated with use of stavudine: Report of four cases. Ann Intern Med 2000;133:192-196.
9. Coghlan ME, Sommadossi JP, Jhala NS, Marey WJ, Saag MS, Johnson VA. Symptomatic lactic acidosis in hospitalized antiretroviral treated patients in human immunodeficiency virus infection: A report of 12 cases. Clin Infect Dis 2001;33:1914-1921.
10. Falco V, Rodriquez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: Report of 12 cases and review of the literature. Clin Infect Dis 2002;34:838-846.
11. John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIV infected patients taking antiretroviral therapy. AIDS 2001;15:717-723.
12. Noguera A, Fortuny C, Sanchez E, et al. Hyperlactatemia in human immunodeficiency virus-infected children receiving antiretroviral treatment. Pediatr Infect Dis 2003;22:778-782.
13. Verma A, Schein RM, Jayaweera DT, Kett DH. Fulminant neuropathy and lactic acidosis associated with nucleoside analog therapy. Neurology 1999;53:1365-1367.
14. Fouty B, Frerman F, Reves R. Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet 1998;352:929-931.
15. Carr A, Morey A, Mallon P, Willis D, Thornburn DR. Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidemia. Lancet 2001;357:1412-1414.
16. Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews CW. Hyperlactemia and hepatic abnormalities in 10 human immunodeficiency virus infected patients receiving nucleoside analogue combination regimen. Clin Infect Dis 2000;31:162-166.
17. Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: The Swiss HIV Cohort Study. Clin Infect Dis 2001;33:1931-1937.
18. Dalton SD, Rahimi AR. Emerging role of riboflavin in the treatment of nucleoside analogue-induced type B lactic acidosis. AIDS Patient Care and STDS 2001;15:611-614.